{"analyses":[{"ciLowerLimit":"1.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.56","estimateComment":"Reference level = Hormone Therapy + Radiation Therapy","groupDescription":"Treatment arms were compared using the log-rank test (one-sided significance level of 0.025).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"1.38","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.1","upperLimit":"55.1","value":"51.7"},{"groupId":"OG001","lowerLimit":"36.1","upperLimit":"42.9","value":"39.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"987"},{"groupId":"OG001","value":"992"}],"units":"Participants"}],"description":"Disease-free failure is defined as documentation of progression (local progression, distant failure, and biochemical failure) or death from any cause. Disease-free survival rates were estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.","id":"OG000","title":"Hormone Therapy + Radiation Therapy"},{"description":"Radiation therapy alone","id":"OG001","title":"Radiation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All eligible patients.","reportingStatus":"POSTED","timeFrame":"From registration to 10 years","title":"Disease-free Survival Rate (10 Years)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}